EpiTherapeutics and Abbott have entered into a partnership to develop anti-cancer drugs by using small-molecule inhibitors against selected epigenetic oncology targets.

Cancer epigenetics is a rapidly emerging research area that focuses on the modification of DNA and chromatin, both of which play a role in tumour development.

Under the agreement, EpiTherapeutics will receive an upfront payment as well as funding of research activities at EpiTherapeutics from Abbott.

In addition, EpiTherapeutics is eligible to receive milestone payments under certain conditions and potential royalties on future revenues.

The collaboration agreement is for a period of three years, and activities will be conducted at EpiTherapeutics and Abbott.

EpiTherapeutics CEO Dr Martin Bonde said the company was very pleased with the collaboration with Abbott, who brings tremendous expertise in the oncology field.

“We look forward to a fruitful collaboration with the aim of developing new anti-cancer drugs within the promising new area of epigenetics,” Bonde added.